This is a preview of subscription content, log in via an institution to check access.
Notes
human epithelial growth factor receptor-2
The study was funded by Novartis Pharmaceuticals Corporation.
Reference
Meyer N, et al. Health care costs and utilization of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents. Cost Effectiveness and Resource Allocation : 28 Apr 2015. Available from: URL: http://dx.doi.org/10.2147/CER.S62090
Rights and permissions
About this article
Cite this article
Burden of HER2+ metastatic breast cancer substantial. PharmacoEcon Outcomes News 727, 8 (2015). https://doi.org/10.1007/s40274-015-2092-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2092-z